References
- American Cancer Society. https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html.
- Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: Current status and future prospects. Oncologist. 2011;16(1):5–24.
- Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother. 2003;4(12):2205–2211.
- Ives NJ, Stowe RL, Lorigan P, et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007;25(34):5426–5434.
- Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.
- Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–1251.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546.
- Keytruda [package insert]. Whitehouse Station, NJ: Merck & Co; 2019. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed October 16, 2019.
- Opdivo [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2019. https://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed October 16, 2019.
- Dobry AS, Zogg CK, Hodi FS, et al. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol Immunother. 2018;67(12):1833–1844.
- Vouk K, Benter U, Amonkar MM, et al. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. J Med Econ. 2016;19(9):900–912.
- Wehler E, Zhao Z, Pinar Bilir S, et al. Economic burden of toxicities associated with treating metastatic melanoma in eight countries. Eur J Health Econ. 2017;18(1):49–58.
- Bilir SP, Ma Q, Zhao Z, et al. Economic burden of toxicities associated with treating metastatic melanoma in the United States. Am Health Drug Benefits. 2016;9(4):203–213.
- Ghate SR, Z Li Z, Tang J, et al. Economic burden of adverse events associated with immunotherapy and targeted therapy for metastatic melanoma in the elderly. Am Health Drug Benefits. 2018;11(7):334–343.
- Vouk K, Benter U, Amonkar MM. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
- Arondekar B, Curkendall S, Monberg M, et al. Economic burden associated with adverse events in patients with metastatic melanoma. J Manag Care Spec Pharm. 2015;21(2):158–164.
- “What Is The Oncology Care Model, And Why Is The Evaluation Important?, “Health Affairs Blog, February 14, 2019.
- Joseph RW, Shillington AC, Macahilig C, et al. Factors associated with immunotherapy selection in patients with advanced melanoma. Immunotherapy. 2018;10(16):1361–1369.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
- Agresti A. 2002. Categorical data analysis. (2nd Ed.). New York (NY): Wiley.
- Wang Lx Quach HT, Moodabigil NV. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. Cancer. 2019.
- Tarhini A, Corman SL, Rao S, et al. Healthcare resource utilization and associated costs in patients with advanced melanoma receiving First‐Line ipilimumab. Journal of Cancer Therapy. 2015;06(10):833–840.
- Toy EL, Vekeman F, Lewis MC, et al. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr Med Res Opin. 2015;31(8):1561–1572.
- Klink AJ, Chmielowski B, Feinberg B. Health care resource utilization and costs in First-Line treatments for patients with metastatic Melanoma in the United States. J Manag Care Spec Pharm. 2019;25(8):869–877.